Independent information services
Guides, comparisons, and research summaries for people looking carefully at ibogaine therapy for PTSD and documented outcomes.
Gentle Clearing 86 offers informational tools, not treatment. The purpose is to make the evidence, its limits, and the safety context easier to inspect before anyone turns a preliminary finding into a conclusion.
01 / Evidence guides
Plain-language summaries separate study findings from study limitations, with attention to sample size, follow-up, comparison groups, and what a reported change can—and cannot—mean. The evidence review on ibogaine and PTSD is a place to begin with the underlying questions.
02 / Decision frameworks
Structured prompts help readers distinguish a personal story, an observational report, and stronger evidence. They are intended to support cautious reading of documented outcomes and their uncertainty, rather than to direct a treatment decision.
03 / Comparisons
Comparisons set ibogaine-related claims alongside the questions used to judge any intervention: who was studied, what was measured, how long outcomes were followed, and what risks were recorded. Our approach to evidence-first context explains why those distinctions matter.
04 / Terminology and safety
Definitions and safety notes clarify terms that are often used loosely. For readers also sorting through dependence-related claims, this context can sit beside information on ibogaine and opioid addiction without treating one topic as proof about another.
Reading research carefully
PTSD is a recognized mental health condition that may follow exposure to traumatic events, as outlined by the National Institute of Mental Health’s PTSD overview. That does not make every study that uses PTSD language equivalent in design or meaning.
Our guides focus on what was measured, when it was measured, and how findings were reported. This includes the difference between symptom scores, participant reports, attrition, and durable outcomes—topics explored in how PTSD outcomes are measured.
Information can clarify a decision landscape. It cannot replace individualized medical assessment or make a treatment claim reliable.
These are recurring lenses for reviewing a claim. They are not a ranking of treatments and do not establish ibogaine as a proven therapy for PTSD.
Reported changes may be meaningful to participants, while still requiring careful interpretation when the study is small, uncontrolled, or brief.
Evidence questions include selection effects, concurrent care, missing follow-up, and whether results would hold in other groups or settings.
Safety, interactions, screening practices, legal status, and care access are part of responsible context; see the ibogaine safety and risk discussion for that wider frame.
No. Gentle Clearing 86 is an independent information resource. It does not provide medical assessment, treatment, referral, or legal advice. The purpose and sourcing approach are described plainly so readers can understand the scope.
It means distinguishing reported findings from what the design, size, follow-up, and limitations of a study can actually support. A documented result is not automatically a confirmed benefit or a prediction for another person.
Ibogaine has potentially serious medical risks and its legal status varies. In the United States, ibogaine appears in the DEA’s controlled-substances schedule list; readers should not treat general information as legal or medical guidance.
Start with the evidence
Explore the research context, study limitations, safety concerns, and uncertainty surrounding ibogaine and PTSD.